Efpia – Sophia

Novo Nordisk A/S NOVO

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries, and markets its products in more than 170 countries.

For more information please visit http://www.novonordisk.com/about-novo-nordisk.html

NOVO PERSONNEL WORKING ON SOPHIA

Dr. Marianne Ølholm Grønning

Role in the project: Industry-lead. Member of the Executive Team and Managing Board

Dr. Matthias Müllenborn

Role in the project: Project management. Member of the Executive Team and Managing Board.

Helene Nao S. Bisgaard

Role in the project: Industry lead on WP1. Member of the Executive Team and Managing Board.

Dr Adam Lenart

Role in the project: WP2 co-lead.

Dr Henrik Agersø

Role in the project: Industry lead on WP4 and WP6.

Dr Cecilie Heerdegen Jepsen

Role in the project: WP8 co-lead

Sherina Kuruvilla

Role in the project: WP7 co-lead

Medtronic International Trading SARL MED

Medtronic plc is a leading medical technology, services and solutions company – alleviating pain, restoring health and extending life for millions of people around the world. The Minimally Invasive Therapies Group (MITG) has been providing health care services from advanced energy-based surgical devices to decades of experience across areas of respiratory care, MITG offer unmatched clinical and economic value through our range of market-leading brands. Our trusted technologies deliver performance and inspire confidence through a comprehensive approach that takes every element of a patient’s health into careful consideration.

MED PERSONNEL WORKING ON SOPHIA

Niall Fahy

Janssen Ignace

Valerie Mauren Monpellier

Boehringer Ingelheim International GmbH BI

Improving the health and quality of life of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company, therefore, concentrates on developing innovative therapies that can extend patients’ lives. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company, therefore, aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com

BI PERSONNEL WORKING ON SOPHIA

Dr. Anita Hennige

Role on the project:WP5 co-lead, member of the Managing Board.

Dr. Joachim Stangier

Role on the project: WP3 co-lead, member of the Managing Board

Eli Lilly and Company LLY

Lilly was founded in 1876, with Headquarters located in Indianapolis, Indiana, U.S.A and with operations based in the US and EU, Eli Lilly is now the 15th largest pharmaceutical company in the world. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Eli Lilly is a research-based pharmaceutical company committed to create value for all stakeholders by accelerating the flow of innovative medicines that provide improved outcomes for individual patients and to help people live longer, healthier, more active lives. Eli Lilly employs approximately 41,000 people worldwide. Approximately 9,000 employees are engaged in research and development. Clinical research is being conducted in more than 55 countries, with research and development facilities located in 6 countries and manufacturing plants located in 13 countries. Lilly products are marketed in 120 countries.

LLY PERSONNEL WORKING ON SOPHIA

Dr Mathijs Bunck

Dr Benjamin Assad Jaghutriz

Dr Irene Romera

Dr Kevin Duffin

Dr Yu Chen

Dr Birgit Steckel-Hamann